➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKesson
Johnson and Johnson
Baxter
Harvard Business School

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 10,144,770

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,770
Title:Chimeric receptors and uses thereof in immune therapy
Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8.alpha.); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3.zeta.). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.
Inventor(s): Campana; Dario (Singapore, SG), Kudo; Ko (Shizuoka, JP), Wilson; Charles (Cambridge, MA), McGinness; Kathleen (Cambridge, MA)
Assignee: National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA)
Application Number:14/516,880
Patent Claims:see list of patent claims

Details for Patent 10,144,770

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial National University of Singapore (Singapore, SG) St. Jude Children\'s Research Hospital (Memphis, TN) Unum Therapeutics Inc. (Cambridge, MA) 2033-10-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,144,770

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Mallinckrodt
Medtronic
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.